References
- McTavish D, Buckley MT, Heel RC. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1991;42:138–170.
- Maton PN. Drug therapy: Omeprazole. N Engl J Med 1991;324:965–975.
- Wallmark B, Lorentzon P, Larsson H. The mechanism of action of omeprazole – a survey of its inhibitory actions in vitro. Scand J Gastroenterol 1985;20(suppl 108):37–52.
- McFarland RJ, Bateson MC, Green JRB, O’Donoghue DP, Dronfield MW, Keeling PWN, Burke GJ, Dickinson RJ, Shreeve DR, Peers EM, Richardson PDI. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. Gastroenterology 1990;98:278–283.
- Lauritsen K, Rune SJ, Bytzer P, Helbaek H, Jansen N. Effect of omeprazole and cimetidine on duodenal ulcer: A double-blind comparative trial. N Engl J Med 1985;312:958–961.
- Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996;31:386–406.
- Blanchi A, Delchier JC, Soule D, Payen D, Bader JD. Control of acute Zollinger-Ellison syndrome with intravenous omeprazole. Lancet 1982;2:1223–1224.
- Oberg K, Lindstrom H. Reduction of gastric hypersecretion in Zollinger-Ellison syndrome with omeprazole. Lancet 1983;1:66–67.
- Castro D, Moreno MA, Torrado S, Lastres JL. Comparison of derivative spectrophotometric and liquid chromatographic methods for the determination of omeprazole in aqueous solutions during stability studies. J Pharm Biomed Anal 1999;21:291–298.
- Riedel A, Leopold CS. Cuantification of omeprazole degradation by enteric coating polymer: A UV-VIS spectroscopy study. Pharmazie 2005;60:126–130.
- Alaa EG, Fawzy EY, Moustafa MM. Spectrophotometric and chromatographic determination of rabeprazole in presence of its degradarion products. J Pharm Biom Anal 2003;31:229–242.
- Kang WK, Kim DS, Kwon KI. Advanced method for determination of omeprazole in plasma by HPLC. Arch Pharm Res 1999;22:86–88.
- USP 23-NF 18. Third supplement. Rockville, MD: United States Pharmacopeia Convention, Inc;1995:2959–2960.
- Gallardo V, Rui, MA, Delgad, AV. Pharmaceutical suspensions and their applications. In: Nielloud F, Marti-Mestres G, editors. Pharmaceutical emulsions and suspensions. New York: Marcel Dekker;2000:409–464.
- Dae YL, Myung GL, Hyun SS, Inchul L. Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: Faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. J Pharm Pharmaceut Sci 2007;10(4):420–433.
- Watanabe K, Furuno K, Eto K, Oishi R, Gomita Y. First-pass metabolism of omeprazole in rats. J Pharm Sci 1994;83:1131–1134.
- Zimmermann A, Walters J, Katona B, Souney P, Levine D. A review of omeprazole use in the treatment of acid disorders in children. Clin Therapeut 2001;23:660–679.
- Zaltin N, Kocer A. Determination of omeprazole in pharmaceuticals by derivative spectroscopy. J Pharm Biomed Anal 1997;16:337–342.
- Delgado AV, Gallardo V, Parera A, González F. A study of the electrocinetic and stability properties of nitrofurantoin suspension. II. Flocculatio and redispersion properties as compared with theorical interactions energy curves. J Pharm Sci 1990;79:709–715.
- Offner CM, Schamare RL, Schwartz JB. Reconstitutable suspension. In: Liebermann HA, editor. Pharmaceutical dosage forms. Disperse system. Vol. 2 ed. New York: Marcel Dekker;1989:317–334.
- Lee DY, Shin HS, Bae SK, Lee MG. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous omeprazole in rats. Biopharm Drug Dispos 2006;27:209–218.
- Hoffmann KJ. Identification of the main urinary metabolites of omeprazole after an oral dose to rats and dogs. Drug Metab Dispos 1986;14:341–348.
- Ruiz MA, Llacer JM, Morales E, Gallardo V. Physical characteristics of polymer complexes in suspension obtained from cellulosic latexes with ondansetron. J Med 2004;15:659–664.
- DiGiacinto JL, Olsen KM, Bergman KL, Hoie EB. Stability of suspension formulations of lansoprazole and omeprazole stored in amber-colored plastic oral syringes. Ann Pharmaceut 2000;34:600–605.
- Clissold SP, Campoli DM. Omeprazole. A preliminary review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986;32:15–47.
- Regardh CG, Gabrielsson M, Hoffman KJ, Lofberg I, Skanberg I. Pharmacokinetics and metabolism of omeprazole in animals and man – an overview. Scand J Gastroenterol 1985;108:79–94.